PI3K

Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that catalyze the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) to generate the second messenger phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P₃). The production of PI(3,4,5)P₃ facilitates the recruitment and activation of pleckstrin homology (PH) domain–containing proteins at the plasma membrane, thereby initiating downstream signaling cascades essential for cellular proliferation, survival, and migration.

PI3Ks are divided into three major classes, among which Class I PI3Ks are most prominently implicated in cancer biology. Class I enzymes comprise four distinct catalytic isoforms: PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ.

Class IA PI3Ks, the subclass most commonly associated with oncogenic signaling, function as heterodimeric lipid kinases composed of a catalytic p110 subunit (p110α, p110β, or p110δ, encoded by PIK3CA, PIK3CB, and PIK3CD, respectively) and a regulatory p85 subunit.

The PI3K signaling pathway plays a central role in diverse biological processes, including cell cycle progression, cellular growth, survival, actin cytoskeletal rearrangement, migration, and intracellular vesicular trafficking.

Frequently Asked Questions
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate phosphatidylinositol lipids to regulate cell growth, survival, metabolism, and immune signaling. PI3K activation leads to downstream AKT and mTOR pathway signaling. Aberrant PI3K signaling is frequently observed in cancer due to PIK3CA mutations, PTEN loss, or receptor tyrosine kinase activation.
Class I PI3Ks include four catalytic isoforms: PI3Kα (PIK3CA) PI3Kβ (PIK3CB) PI3Kδ (PIK3CD) PI3Kγ (PIK3CG) PI3Kα and β are broadly expressed, while PI3Kδ and γ are enriched in leukocytes and play critical roles in immune regulation. Isoform selectivity is an important consideration in drug development due to toxicity and immune effects.
PI3K inhibitors can be classified as: Pan-PI3K inhibitors Isoform-selective inhibitors (α, β, δ, γ) Dual PI3K/mTOR inhibitors Irreversible inhibitors Selectivity influences therapeutic window and toxicity profile.
While PI3K inhibitors block upstream lipid kinase activity, mTOR inhibitors act downstream at the level of mTORC1 or mTORC2. Dual PI3K/mTOR inhibitors target both nodes of the pathway and may achieve broader pathway suppression.

Items 176-200 of 411

  • PI3K/Akt/mTOR-IN-3
    Cat. No.
    A25637

    PI3K/Akt/mTOR-IN-3

    PI3K/Akt/mTOR-IN-3 is a potent inhibitor targeting the PI3K/AKT/mTOR signaling pathway. It demonstrates significant biological activity, exhibiting IC50 values of 0.77 μM, 1.23 μM, and 4.57 μM in MCF-7, HeLa, and HepG2 cells, respectively. Additionally, this compound effectively inhibits the migration of MCF-7 and HeLa cells at a concentration of 4 μM, while also inducing apoptosis and causing cell cycle arrest in the S phase. This makes PI3K/Akt/mTOR-IN-3 a valuable tool for research in cancer biology and therapeutic development.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3K/AKT-IN-3
    Cat. No.
    A25642

    PI3K/AKT-IN-3

    PI3K/AKT-IN-3 is a selective inhibitor of the PI3K/AKT signaling pathway, known to induce both autophagy and apoptosis in various cell types. This compound is primarily utilized in cancer research to study the effects of PI3K/AKT inhibition on tumor growth and cell survival mechanisms. Its application extends to exploring therapeutic strategies targeting this critical signaling pathway in cancer treatment.

    Out of stock

    All 3 sizes
  • Asperosaponin V
    Cat. No.
    A25644

    Asperosaponin V

    Asperosaponin V is an indirect modulator of key signaling pathways, including PI3K/AKT, BMP-2/p38, and ERK 1/2. This compound stimulates the proliferation of marrow stromal cells and promotes differentiation into osteoblasts, making it valuable for studying bone metabolism. Asperosaponin V holds potential for applications in osteoporosis research and fracture healing studies.

    Out of stock

    All 3 sizes
  • Anticancer agent 235
    Cat. No.
    A25652

    Anticancer agent 235

    Anticancer agent 235 is a modulator of the PI3K/AKT/mTOR signaling pathway. It promotes reactive oxygen species (ROS) generation and decreases mitochondrial membrane potential, leading to reduced proliferation of cancer cell lines including HCT116, Caco-2, AGS, and SMMC-772 with IC50 values ranging from 0.35 to 26.9 μM. Furthermore, Anticancer agent 235 effectively induces G2/M cell cycle arrest and apoptosis in HCT116 cells, making it a valuable tool for cancer research applications.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Monomethyl lithospermate
    Cat. No.
    A25659

    Monomethyl lithospermate

    Synonyms: Lithospermic acid monomethyl ester

    Monomethyl lithospermate serves as a PI3K/AKT pathway activator, which is crucial for neuroprotection following nerve injury. This compound enhances the viability of SH-SY5Y neuroblastoma cells by preserving mitochondrial membrane potential and inhibiting apoptosis. Additionally, monomethyl lithospermate reduces oxidative stress in brain tissue of rats subjected to middle cerebral artery occlusion, demonstrating efficacy in mitigating nerve damage associated with ischemic stroke.

    1 mg
    $285.00
    5 mg
    $720.00
    All 2 sizes
  • PI3Kδ-IN-24
    Cat. No.
    A25668

    PI3Kδ-IN-24

    PI3Kδ-IN-24 is a highly selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) with an IC50 of 0.1 nM. This compound demonstrates notable antiproliferative effects in cancer cell lines with elevated PI3Kδ expression. By inhibiting PI3Kδ, PI3Kδ-IN-24 effectively lowers phosphorylated AKT levels and promotes cell cycle arrest and apoptosis in tumor cells. Its applications are particularly relevant in cancer research, including studies involving diffuse large B-cell lymphoma (DLBCL).

    Out of stock

    All 3 sizes
  • X-370
    Cat. No.
    A25681

    X-370

    X-370 is a PI3Kδ inhibitor (IC50 = 7 nM). X-370 inhibits the survival of leukemia cells, inducing G1 arrest and apoptosis. X-370 blocks PDK1 binding and phosphorylation of MEK1/2, eliminating Akt and Erk1/2 signaling. X-370 can be used in research on B-cell acute lymphoblastic leukemia (B-ALL).

    Out of stock

    All 3 sizes
  • RLX hydrochloride
    Cat. No.
    A25685

    RLX hydrochloride

    Synonyms: PD 139530 hydrochloride

    RLX hydrochloride is a potent inhibitor of the PI3K/Akt/FoxO3a signaling pathway, which plays a critical role in cellular growth and survival. This compound demonstrates significant therapeutic potential in experimental colon cancer by modulating the tumor microenvironment and enhancing the efficacy of cancer immunotherapy. Additionally, RLX hydrochloride can improve the retention of therapeutic agents within tumors when utilized with advanced nanoparticle delivery systems. It may also be effectively combined with other treatment modalities, such as chemotherapy and radiotherapy, to optimize overall cancer therapy outcomes.

    1 mg
    $155.00
    5 mg
    $395.00
    All 7 sizes
  • DHW-208
    Cat. No.
    A25688

    DHW-208

    PI3K-IN-4 is a potent Pan-PI3K inhibitor. PI3K-IN-4 has high activity for three PI3K isoforms with the IC50 values of picomole. PI3K-IN-4 shows superior inhibitory activity against PI3Kα (IC50 = 0.20 nM), PI3Kβ (IC50 = 2.99 nM), PI3Kδ (IC50 = 0.48 nM) and PI3Kγ (IC50 = 0.58 nM) and has no significant activity against EGFR. PI3K-IN-4 inhibits cancer cell growth though PI3K/Akt signaling pathway, leading to the inhibition of colony formation and the induction of apoptosis. PI3K-IN-4 can be used for lung, colon and breast cancer research.

    Out of stock

    All 3 sizes
  • PI3K-IN-29
    Cat. No.
    A25698

    PI3K-IN-29

    PI3K-IN-29 is a potent inhibitor of Phosphoinositide 3-kinase (PI3K), effectively disrupting the PI3K/Akt signaling pathway. It demonstrates significant cytotoxic activity against various cancer cell lines, including U87MG, HeLa, and HL60, with IC50 values of 0.264 µM, 2.04 µM, and 1.14 µM, respectively. This compound is valuable for research applications involving cancer biology and therapeutic interventions targeting the PI3K pathway.

    Out of stock

    All 3 sizes
  • Acetyl-Exenatide
    Cat. No.
    A25712

    Acetyl-Exenatide

    Acetyl-Exenatide is an acetylated derivative of Exenatide, targeting the PI3K/Akt signaling pathway. This compound exhibits insulin-mimetic properties and is instrumental in type 2 diabetes research. Acetyl-Exenatide promotes Th17 differentiation while inhibiting Treg differentiation, and downregulates the phosphorylation of PI3K/Akt/FoxO1, making it a valuable tool for elucidating mechanisms underlying metabolic disorders.

    Out of stock

    All 3 sizes
  • VVD-484
    Cat. No.
    A25718

    VVD-484

    VVD-484 is a selective inhibitor targeting PI3K p110α, exhibiting an IC50 of 0.59 μM against human targets. Classified as a "silent ligand," it forms a covalent bond with Cys242 of PI3K p110α, maintaining the p110α-KRASG12C interaction. VVD-484 effectively inhibits AKT phosphorylation at S473 via a RAS-independent pathway, making it a valuable tool in the research of HER2-overexpressing cancers.

    Out of stock

    All 3 sizes
  • PI3K-IN-56
    Cat. No.
    A25722

    PI3K-IN-56

    PI3K-IN-56 is a potent and selective irreversible inhibitor of phosphoinositide 3-kinase (PI3K), exhibiting oral bioavailability. This compound effectively blocks the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) and disrupts downstream AKT signaling pathways. Its potential applications in cancer research make PI3K-IN-56 particularly valuable for studies focusing on PI3Kα-driven malignancies, including breast and ovarian cancers.

    Out of stock

    All 3 sizes
  • Calebin A
    Cat. No.
    A25726

    Calebin A

    Calebin A is a potent inhibitor of the PI3K/Akt/mTOR pathway, as well as MAPK and NF-κB signaling pathways. It exhibits significant anti-tumor activity through epigenetic regulation and can suppress apoptosis while inhibiting autophagy. Additionally, Calebin A modulates adipogenesis, enhances thermogenic processes, and supports gut microbiota. This compound is suitable for research in various domains, including osteoarthritis, Alzheimer's disease, type 2 diabetes, malignant peripheral nerve sheath tumors, and colorectal cancer.

    1 mg
    $155.00
    5 mg
    $395.00
    All 6 sizes
  • PLAGL2-IN-1
    Cat. No.
    A25733

    PLAGL2-IN-1

    PLAGL2-IN-1 is a selective inhibitor of pleiomorphic adenoma-like protein 2 (PLAGL2), exhibiting a Kd of 2.23 µM. This compound effectively suppresses PLAGL2 transcriptional activity, leading to G0/G1 cell cycle arrest and apoptosis in hepatocellular carcinoma (HCC) cells. Additionally, PLAGL2-IN-1 disrupts extracellular matrix organization and inhibits the PI3K-AKT pathway by reducing AKT phosphorylation. It demonstrates significant efficacy in inhibiting tumor growth in an HCCLM3 xenograft mouse model, making it a valuable tool for research focused on HCC.

    Out of stock

    All 3 sizes
  • PI3Kδ-IN-10
    Cat. No.
    A25771

    PI3Kδ-IN-10

    PI3Kδ-IN-10 is a potent and orally bioavailable inhibitor of the PI3Kδ enzyme, exhibiting an IC50 value of 2 nM. This compound effectively inhibits the downstream AKT signaling pathway, leading to the induction of apoptosis in hepatocellular carcinoma models. Due to its mechanism of action, PI3Kδ-IN-10 is valuable for investigating the role of PI3Kδ in cancer biology and therapeutic development.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • RLX
    Cat. No.
    A25782

    RLX

    Synonyms: PD 139530

    RLX (PD 139530) is a potent inhibitor of the PI3K/Akt/FoxO3a signaling pathway, exhibiting significant therapeutic potential in colon cancer models. This compound can effectively modulate the tumor microenvironment, thereby enhancing the efficacy of cancer immunotherapy. Additionally, RLX improves the retention time of therapeutic agents in tumors through advanced nanoparticle delivery systems and can be combined with various treatment modalities, such as chemotherapy and radiotherapy, to synergistically enhance cancer treatment outcomes.

    1 mg
    $235.00
    5 mg
    $590.00
    All 6 sizes
  • DHW-221
    Cat. No.
    A25783

    DHW-221

    DHW-221 is a potent dual inhibitor of PI3K and mTOR, demonstrating low nanomolar potency across all four Class I PI3K isoforms (PI3Kα, IC50 = 0.50 nM; PI3Kβ, IC50 = 1.9 nM; PI3Kγ, IC50 = 1.8 nM; PI3Kδ, IC50 = 0.74 nM) and mTOR (IC50 = 3.9 nM). This compound exhibits significant antitumor activity by disrupting the PI3K/Akt/mTOR signaling pathway, promoting mitochondrial apoptosis and paraptosis via endoplasmic reticulum stress and MAPK signaling, while also hindering cell cycle progression, migration, invasion, and angiogenesis. DHW-221 serves as a valuable tool in research related to non-small cell lung cancer (NSCLC), colon cancer, and breast cancer.

    Out of stock

    All 3 sizes
  • Zandelisib hydrochloride
    Cat. No.
    A25784

    Zandelisib hydrochloride

    Synonyms: ME-401 hydrochloride; PWT-143 hydrochloride

    Zandelisib hydrochloride is a selective, non-covalent inhibitor of PI3Kδ, known for its oral bioavailability. By effectively inhibiting AKT phosphorylation, Zandelisib hydrochloride disrupts downstream signaling pathways, making it a valuable tool for investigating the role of the PI3K pathway in various malignancies. This compound is particularly relevant in research focused on relapsed and refractory B-cell lymphoma, enabling studies on tumor behavior and therapeutic responses.

    Out of stock

    All 3 sizes
  • PI3K/AKT-IN-5
    Cat. No.
    A25786

    PI3K/AKT-IN-5

    PI3K/AKT-IN-5 is a selective inhibitor of the PI3K/AKT signaling pathway. It demonstrates potent anti-cancer activity, particularly in colorectal cancer models, by significantly inhibiting cell colony formation, inducing G2/M phase cell cycle arrest, and promoting apoptosis. This compound serves as a valuable tool for research into the mechanisms of colorectal cancer progression and treatment.

    Out of stock

    All 3 sizes
  • Wortmannin-Rapamycin Conjugate 1
    Cat. No.
    A25788

    Wortmannin-Rapamycin Conjugate 1

    Wortmannin-Rapamycin Conjugate 1 is a furan ring-opened derivative that targets the PI3K/AKT signaling pathway with potent antitumor activity. Its ability to inhibit AKT phosphorylation makes it a valuable reagent for cancer research. Additionally, this compound exhibits favorable water solubility, enhancing its applicability in various biological assays. Researchers can utilize Wortmannin-Rapamycin Conjugate 1 to investigate mechanisms of tumor growth and therapeutic responses.

    0.5 mg
    $265.00
    1 mg
    $505.00
    All 3 sizes
  • PI3Kδ-IN-11
    Cat. No.
    A25789

    PI3Kδ-IN-11

    PI3Kδ-IN-11 is a potent and selective inhibitor of the PI3Kδ isoform, exhibiting an IC50 value of 27.5 nM. This compound effectively blocks the PI3K/Akt signaling pathway in a dose-dependent manner. PI3Kδ-IN-11 is particularly useful for studying B and T cell-related malignancies, providing valuable insights into therapeutic strategies targeting this pathway.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • JE-133
    Cat. No.
    A25792

    JE-133

    JE-133 is an optically active isochromane-2H-chromene conjugate that acts as a neuroprotectant by targeting the PI3K/Akt and MAPK signaling pathways. This compound exhibits significant antioxidant and anti-inflammatory properties, effectively inhibiting neuronal oxidative damage. Additionally, JE-133 modulates neuroinflammation induced by lipopolysaccharide (LPS) through the regulation of the JAK/STAT and Nrf2 signaling pathways, making it a valuable tool for research into neuroprotective mechanisms.

    Out of stock

    All 3 sizes
  • Alborixin
    Cat. No.
    A25800

    Alborixin

    Alborixin is a potent inhibitor of the PI3K-AKT signaling pathway that promotes autophagy. It facilitates the clearance of intracellular and extracellular amyloid-β by upregulating key autophagy-related proteins such as BECN1, ATG5, and ATG7, while enhancing lysosomal activity. This mechanism yields a reduction in amyloid-β-mediated neurotoxicity, positioning Alborixin as a valuable tool for research related to Alzheimer's disease and other neurodegenerative conditions.

    Out of stock

    All 3 sizes
  • PI3Kα-IN-28
    Cat. No.
    A25816

    PI3Kα-IN-28

    PI3Kα-IN-28 is a potent dual-target inhibitor of PI3K and BRD4. This compound effectively suppresses cell proliferation in various cancer cell lines, including KYSE180 and KYSE450, while also inhibiting migration and colony formation. Additionally, PI3Kα-IN-28 induces G0/G1 phase cell cycle arrest and promotes cellular senescence by enhancing the proportion of senescent cells. Mechanistically, it decreases the levels of p-AKT and c-Myc, while activating the AMPK-p27 pathway, making it a valuable tool for cancer research, particularly in esophageal cancer studies.

    Out of stock

    All 3 sizes

Items 176-200 of 411

Added to your cart

View Cart Checkout

    Loading...